Estrella Immunopharma, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, reporting beneficial ownership of 4.99% of Estrella Immunopharma, Inc. common stock.
NASDAQ
Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 9.99% of Estrella Immunopharma, Inc.'s common stock as of March 31, 2026.